Novel Targets for Innovative Retinopathy Treatment

Background

Retinopathies are a group of retinal diseases characterized by progressive loss of visual acuity, often leading to blindness. These diseases can be triggered by genetic conditions such as retinitis pigmentosa or by environmental factors like retinopathy of prematurity (ROP). Approximately 1 in 20 people suffer from some form of retinal disease, making it a significant area of unmet medical need. The current market for solutions primarily revolves around managing symptoms, with treatments like anti-VEGF injections used to control abnormal blood vessel growth. Despite their efficacy, these treatments require repeated administration and may have side effects. Furthermore, they do not address the underlying inflammatory processes contributing to disease progression, leaving room for improved therapeutic interventions.

Technology Overview

This technology targets the activation of myeloid lineage cells in the retina, which is a key driver of neovascularization and vision loss. This is achieved by decreasing the expression or activity of specific factors like secreted phosphoprotein 1 (Spp1), triggering receptor expressed on myeloid cells 2 (Trem2), translocator protein (Tspo), and signal transducer and activator of transcription 3 (STAT3) in these cells, effectively mitigating inflammatory cascades.

A crucial component of our approach involves modulating suppressor of cytokine signaling 3 (SOCS3), a protein known for its protective effects on the retina through inhibition of inflammatory cytokine release. By enhancing SOCS3 activity, the technology further suppresses harmful immune responses that contribute to retinal damage. Proof-of-concept studies have demonstrated a reduction in retinal neovascularization and improvement in retinal function, highlighting the potential of this dual-action approach to not only halt disease progression but also enhance retinal health.

Applications

- Treatment of retinopathy of prematurity (ROP)

- Management of age-related macular degeneration (AMD)

- Therapy for retinitis pigmentosa

- Control of diabetic retinopathy

Advantages

- Targets the root cause of inflammation-driven neovascularization

- Enhances SOCS3 activity to provide additional protective effects

- Offers potential for long-term efficacy with reduced treatment frequency

- Combines innovative RNA-based therapies with antibody-mediated strategies for comprehensive treatment

- Possibility of personalized treatment by collecting and modifying patient-specific myeloid cells

By capitalizing on the dual mechanism of reducing harmful activation and enhancing protective pathways in immune cells, this solution represents a groundbreaking advancement in the management of retinopathies, aiming to significantly improve patient outcomes where current therapies fall short.